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Background: The cardiac PRKAG2 mutation in the γ2-subunit of adenosine monophosphate activated kinase
(AMPK) is characterized by excessive glycogen deposition, hypertrophy, frequent arrhythmias, and progressive
conduction system disease. We investigated whether myocardial glucose uptake (MGU) was augmented following
insulin stimulation in a mouse model of the PRKAG2 cardiac syndrome.
Methods: Myocardial and skeletal muscle glucose uptake was assessed with 2-[18F]fluoro-2-deoxyglucose positron
emission tomography imaging in n = 3 transgenic wildtype (TGwt) vs n = 7 PRKAG2 mutant (TGmut) mice at
baseline and 1 week later, 30 min following acute insulin. Systolic function, cardiac glycogen stores, phospho-AMPK
α, and insulin-receptor expression levels were analyzed to corroborate to the in vivo findings.
Results: TGmut Patlak Ki was reduced 56% at baseline compared to TGwt (0.3 ± 0.2 vs 0.7 ± 0.1, t test p = 0.01).
MGU was augmented 71% in TGwt mice following acute insulin from baseline (0.7 ± 0.1 to 1.2 ± 0.2, t test p < 0.05).
No change was observed in TGmut mice. As expected for this cardiac specific transgene, skeletal muscle was
unaffected at baseline with a 33% to 38% increase (standard uptake values) for both genotypes following insulin
stimulation. TGmut mice had a 47% reduction in systolic function with a fourfold increase in cardiac glycogen stores
correlated with a 29% reduction in phospho-AMPK α levels. There was no difference in cardiac insulin receptor
expression between mouse genotypes.
Conclusions: These results demonstrate a correlation between insulin resistance and AMPK activity and provide the
basis for the use of this animal model for assessing metabolic therapy in the treatment of affected PRKAG2 patients.
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Insulin resistance is strongly associated with the devel-
opment of heart failure due to cardiotoxicity induced by
the hyperglycemic state with subsequent modification of
contractile proteins [1] and development of cardiac dys-
function [2]. The potential to decrease insulin resistance
and increase glucose uptake has recently been sought* Correspondence: jdasilva@ottawaheart.ca
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in any medium, provided the original work is pthrough the upregulation of adenosine monophosphate
activated kinase (AMPK) activity [3]. AMPK acts as a
cellular fuel gauge, tightly regulating glucose and fatty acid
metabolism. Indeed, metformin, a common pharmaco-
logical treatment for type 2 diabetes, targets AMPK
subsequently, increasing insulin sensitivity [4-6].
The critical importance of AMPK function in the heart
was highlighted by the observation that genetic muta-
tions in the PRKAG2 gene, encoding the gamma-2 regu-
latory subunit of AMPK, gives rise to a novel cardiac
glycogenosis syndrome in humans [7,8]. Affected indi-
viduals exhibit varying degrees of cardiac hypertrophy,n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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gressive conduction system disease leading to pacemaker
implantation. In some cases, the need for heart trans-
plantation or premature sudden death may occur [9-11].
On gross pathologic and histologic assessment, the hall-
mark of the PRKAG2 cardiac syndrome is the diffuse
and extensive glycogen deposition throughout all four
cardiac chambers [12].
Using 2-[18F]fluoro-2-deoxyglucose (FDG) and positron
emission tomography (PET) imaging, human patients
with the Arg302Gln mutation of PRKAG2 exhibited a
45% reduction in myocardial glucose uptake compared to
control subjects [13].
This study sought to evaluate whether the PRKAG2
myocardium is responsive to insulin-mediated cardiac
glucose uptake. To address this, a transgenic mouse
model of the human PRKAG2 cardiac syndrome was
assessed with in vivo FDG PET imaging at baseline and
1 week later following insulin stimulation. We further
evaluated whether this response correlated to changes in
protein expression of activated AMPK, insulin receptors,
and cardiac glycogen content.
Methods
Animal model
All animal experiments described herein were conducted
according to the guidelines of the University of Ottawa
Animal Care Committee and the Canadian Council
on Animal Care for the use and care of laboratory
animals. All animals were maintained on a 12-h light/
dark cycle with chow (Harlan Tekland #2019) and water
ad libitum.
Transgenic mice were generated as previously de-
scribed [14] using a cardiac-specific α-myosin heavy chain
promoter, PRKAG2 cDNA, 3′UTR human growth
hormone. These mice, therefore, have the transgene only
in the myocardium. Transgenic mutant (TGmut) mice
express the mutant PRKAG2 gene (substitute of arginine
for glutamine at residue 302), with transgenic wildtype
(TGwt) mice expressing the normal human PRKAG2
complementary deoxyribonucleic acid (cDNA). PCR was
performed on the genomic DNA isolated from weanling
mouse tail snips with the QIAGEN DNeasy kit (Venlo,
Netherlands) with the product sequenced. All studies
herein were performed in mice at 5 to 8 months of age
(TGwt n = 7, TGmut n = 11).
Echocardiography
Echocardiography images were obtained with the Vevo
770 imaging system (VisualSonics, Toronto, ON,
Canada) using a 707 transducer. Mice (TGwt n = 4,
TGmut n = 4) were anesthetized and maintained
throughout experimental procedures with 1% to 2%
isoflurane. Long-axis B-mode images were assessed withthe commercially available VisualSonics cardiac mea-
surements program to determine left ventricle (LV)
fractional shortening and endocardial volume.
Small animal PET imaging
Small animal PET FDG imaging was conducted with
the InveonTM DPET small animal scanner (Siemens,
Knoxville, TN, USA). Mice (TGwt n = 3, TGmut n = 7)
were scanned under anesthetic (1% to 2% isoflurane, 2 to
2.5 mL/min oxygen) at baseline and 1 week later, 30 min
following an acute intraperitoneal injection with short-
acting insulin (8 mU/g body weight; Novolin ge Toronto,
Novo Nordisk, Denmark) [15]. A 60-min list-mode acqui-
sition was started together with a 10- to 20-s tail vein
injection of FDG (25.3 ± 7.9 MBq in 150 μL). List data
were sorted into 26 dynamic frames (12 × 10, 3 × 60,
11 × 300 s) and reconstructed using OSEM3D with 10
iterations, 16 subsets, and zoom of 2.5 with a 128 × 128
matrix, resulting in 0.35 mm transaxial pixel size. Images
were corrected for radioactive decay, random coinci-
dences, and dead-time losses using the vendor software
(IAW version 1.5). Blood glucose concentration was mea-
sured (mmol/L) prior to FDG injection with a small drop
of blood from the saphenous vein using Advantage blood
glucose strips (AccuChek, Roche Diagnostics, Laval, QC,
Canada).
Image analysis
Myocardial uptake images of the LV were formed by
averaging the last 5 min of scan data using FlowQuant©
semi-automated software [16]. The location, orientation,
and size of the LV were automatically determined by fit-
ting ellipses to the myocardium in the transverse, verti-
cal long axis and horizontal long axis planes. Transverse
uptake images were reoriented automatically into short-
axis (SA) sections generating LV slices from the apex to
the base plane. Polar maps of the relative uptake activity
(%) were formed from the sampled data. The sampling
points were then applied to all-time frames to generate
myocardial time-activity curves (TACs). Myocardial
TACs were compared using standard uptake values
(SUV) calculated by dividing the activity concentration
in the region of interest (Bq/cc) by the activity concen-
tration per body weight injected into the animal (Bq/g).
Skeletal muscle SUV values (Siemens IRW, Munich,
Germany) were also evaluated at 7.5 and 60 min at both
baseline and following insulin as a control region of
interest for the cardiac genetic phenotype. Blood regions
of interest were derived with the Siemens IRW software
using the proximal vena cava and the resulting blood
TACs were imported into FlowQuant© image analysis
software as previously described [16]. Patlak kinetic ana-
lysis [17] was performed on the myocardium at 1.58 to
7.5 min from the reconstructed images (FlowQuant©).
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the myocardial activity (Cm[t]) corrected for blood
activity (Cb[t]) and the integral of blood activity (Cb[t])
at time (t) becomes linear, with the slope representative
of the uptake rate constant Ki.
Protein expression and cardiac glycogen levels
Mice (TGwt n = 4, TGmut n = 4) were euthanized by
decapitation with hearts dissected out, then placed
immediately into liquid nitrogen for storage at −80°C.
Tissue was ground using a mortar and pestle under
liquid nitrogen. Glycogen content was determined using
an amyloglucosidase digestion method as previously
described [18]. Briefly, 10 to 50 mg of ground cardiac
tissue was homogenized in a 1:9 (wt./vol.) ratio of PBM
buffer (20 mM KH2PO4, 10 μM CaCl2, 1 mM MgCl2,
pH 6.1). Tissue homogenate (50 μL) was boiled for 20
min in 30% KOH (wt./vol.) saturated with anhydrous
Na2SO4. The remainder of tissue homogenate was used
to determine protein concentration with a bicinchoninic
acid (BCA) assay. Glycogen was precipitated with 95%
ethanol (vol./vol.), centrifuged at 4,000 × g for 15 min at
4°C. The glycogen pellet was dissolved in double distilled
H2O and incubated at 100°C for 20 min with 0.2%
anthrone (wt./vol.) in H2SO4. Absorbance was read at
595 nm to determine glycogen concentration of samples
relative to an oyster glycogen standard curve (Sigma
Aldrich, Canada) and normalized to protein content
(microgram of glycogen per microgram of protein).
Ground tissue was homogenized in buffer (10 mM
Tris–HCl, 50 mM NaF, 1 mM EDTA, 10 mM
dithiothreitol, 10% glycerol (vol./vol.), pH 7.5 at 4°C)
and a BCA assay performed to determine protein
concentration. Tissue lysate (20 μg) was applied to
each lane of an 8% SDS-polyacrylamide gel with separated
bands of proteins transferred to a polyvinylidene fluoride
membrane. Blocked membranes were incubated with
either AMPK α (1:1,000), phosphorylated-AMPK α (Thr
172) (1:500), or insulin receptor β (1:1,000) (Cell Signaling
Technology, Danvers, MA, USA). A mouse glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) antibody
(Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA)
was used as a loading control. Membranes were analyzed
using a Fluor Chem HD image system (Alpha Innotech,
San Leandro, CA, USA). Data were expressed as a ratio of
target protein to GAPDH protein band intensities,
normalized to the mean of TGwt controls for each
membrane.
Statistical analysis
Curve fitting with FlowQuant© software was performed
using MATLAB (The MathWorks, Natick, MA, USA).
All data are expressed as mean ± standard deviation.





Cardiac function, volume, and wall thickness were
assessed with echocardiography in vivo. Examples of
long-axis B-mode (Figure 1A) images are displayed for a
TGwt and TGmut mouse. The Arg302Gln PRKAG2
TGmut mice have a 96% increase in the LV volume
compared to TGwt controls (76.3 ± 29.3 μL vs 38.9 ±
7.3 μL; t test p < 0.05) (Figure 1B). Additionally, these
mice display an overall reduction in cardiac systolic
function with LV fractional shortening reduced to 47%
(TGwt 33.1% ± 5.1% vs TGmut 17.7% ± 3.3%; t test p <
0.01) (Figure 1C) with similarity in heart rates between
groups (TGwt 407 ± 35 bpm, TGmut 360 ± 69 bpm; p =
0.27). There was no difference in LV wall thickness in
TGmut except for 30% significant reduction in the mid
septal wall (1.4 ± 0.3 vs 0.9 ± 0.2; t test p < 0.05)
(Figure 1D).
Myocardial glucose uptake is reduced in TGmut mice with
no response to insulin stimulation
There was no difference between baseline and follow-up
scans or between genotype with respect to body weight
at time of scan (p > 0.05 one-way ANOVA, Bonferrroni;
Table 1). Blood glucose levels were not significantly
different between TGwt and TGmut mice at baseline
(Table 1), both groups showing a similar decrease of
60% to 70% in blood glucose values following insulin
pretreatment prior to FDG injection (Table 1). Represen-
tative cardiac images in TGwt (Figure 2A) and TGmut
(Figure 2C) are depicted in axial, coronal, and sagittal
views at baseline and following insulin stimulation. Con-
trary to TGmut mice, SUV analysis of the myocardial
curves displays an increase in initial uptake rate with
insulin stimulation in TGwt mice (Figure 2B, D). In fact,
a 43% reduction in myocardial glucose uptake following
acute insulin stimulation at 60 min was observed in
TGmut mice (Table 2). Both TGwt and TGmut show a
31% to 38% increase in skeletal muscle SUV values with
insulin stimulation at both 7.5 and 60 min (Table 2).
Patlak kinetic analysis was used to determine differences
in myocardial glucose uptake rate. Representative Patlak
Ki polar maps and linear plots of normalized activity in
high-uptake regions between 1.58 and 7.5 min are
displayed (Figure 3). Patlak polar maps qualitatively
show an increase in Ki values with insulin in TGwt mice
(Figure 3A, B) but not observed in the TGmut mice
(Figure 3C, D). In all cases, there was an excellent
linear fit in the time frame of 1.5 to 7.5 min. At





















































































Figure 1 Arg302Gln PRKAG2 increases LV volume and reduces cardiac function. Representative echocardiography M-mode images (A) of a
TGwt and TGmut mouse. Using B-mode echocardiography measurements of the long axis, comparison of LV volume (B), fractional shortening
(C), and wall thickness (D). TGwt n = 4 and TGmut n = 4. *p < 0.05, Student's t test.
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Table 1 Body weight and blood glucose values prior to
injection of FDG
Mouse Genotype Body weight (g) Pre-FDG blood
glucose (mmol/L)
TGwt 36.4 ± 8.3 14.1 ± 1.3
TGwt insulin 37.7 ± 8.9 4.0 ± 0.3*
TGmut 32.2 ± 4.5 10.4 ± 3.4
TGmut insulin 33.2 ± 4.1 4.6 ± 1.9*
*p < 0.05 by ANOVA and after Bonferroni correction.
Table 2 Myocardium and skeletal muscle FDG standard
uptake values (SUV)
SUV Myocardium Muscle
SUV 7.5 min p.i.
TGwt 9.6 ± 2.2 0.5 ± 0.1
TGwt insulin 16.9 ± 2.8* 0.8 ± 0.2*
TGmut 5.8 ± 1.6** 0.7 ± 0.1
TGmut insulin 6.4 ± 1.4 1.1 ± 0.5*
SUV 60 min p.i.
TGwt 20.4 ± 3.3 0.7 ± 0.2
TGwt insulin 21.8 ± 4.3 1.1 ± 0.2*
TGmut 12.6 ± 4.1 1.0 ± 0.2
TGmut insulin 7.2 ± 2.6* 1.5 ± 0.6*
p.i., post injection; *p < 0.05 vs non-insulin treated baseline with Student's t
test; **p < 0.05 vs TGwt with Student's t test.
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display an increase of 71% from baseline following
insulin stimulation while TGmut showed no change
in cardiac uptake rates following insulin stimulation
(Table 3).
Glycogen deposition and protein expression
There was a fourfold increase in cardiac glycogen
levels in the TGmut mice compared to TGwt hearts
(0.46 ± 0.07 vs 0.11 ± 0.05; t test p < 0.001). A 29%
reduction in phosphorylation of AMPK α on Thr 172




























































Figure 2 Representative microPET FDG images and SUV time-activity
Representative cardiac FDG images of TGwt (A) and TGmut mice (C) at ba
axial, coronal, and sagittal views and standardized to the same scale. Myoc
(D), respectively, over 60 min using SUV. TGwt n = 3 and TGmut n = 7.found in TGmut mice compared to TGwt hearts
(1.1 ± 0.2 vs 0.8 ± 0.2; t test p < 0.05) (Figure 4A).
Protein expression of cardiac insulin receptor β
was not affected by the PRKAG2 genotype with no
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Figure 3 Representative FDG Patlak Ki polar maps and linear plots. FDG Patlak Ki polar maps for TGwt baseline (A), TGwt with insulin
(B), TGmut baseline (C), and TGmut following insulin (D). Representative mean derivation of Patlak analysis showing a linear plot of normalized
activity vs normalized time are shown beside the polar map for each state. Solid lines represent the fit of the Patlak Ki to the linear curves at
1.58 to 7.5 min. The slope of this relationship quantifies Patlak Ki. TGwt n = 3 and TGmut n = 6.
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Table 3 Myocardial FDG Patlak kinetic analysis (1.58 to
7.5 min)
Mouse Genotype Baseline Insulin
TGwt 0.7 ± 0.1 1.2 ± 0.1*
TGmut 0.3 ± 0.2** 0.4 ± 0.2
*p < 0.05 vs non-insulin-treated baseline with Student's t test; **p < 0.05 vs
























































































Figure 4 Protein expression of AMPK and insulin receptor β.
Relative protein expression normalized by measured GAPDH levels
and then normalized to TGwt for phospho-AMPK α levels expressed
to total AMPK (A) and insulin-receptor protein expression (B). TGwt
n = 4 and TGmut n = 4; *p < 0.05, Student's t test.
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Central to cardiac metabolism, AMPK is activated in
response to energy deprivation to rapidly modulate
cardiac metabolism [19]. Activated AMPK is known to
enhance translocation of GLUT4 to the cell membrane
to facilitate glucose uptake [20]. In the current study, we
evaluated mice at 5 to 8 months of age and demon-
strated a reduction in the phosphorylation of the α sub-
unit of AMPK of 29% that agrees with a previously
published study using the Arg302Gln PRKAG2 mice at
more than 8 weeks of age [21]. With a reduction in
AMPK activity, our data establish a 56% reduction in
glucose uptake with FDG PET imaging in TGmut mice
compared to TGwt.
As GLUT transporter efficiency is the rate-limiting
step for glucose uptake and the insulin-dependent trans-
porter GLUT4 is the most abundant transporter in the
mouse myocardium, we sought to determine if FDG
uptake could be increased in the PRKAG2 mutant
mouse hearts following acute insulin stimulation. We
found that unlike TGwt mice, where there was a 71% to
76% increase in Patlak Ki and SUV values from baseline,
TGmut mice displayed no increase in FDG uptake
following insulin stimulation. We additionally deter-
mined that the protein expression of the cardiac insu-
lin receptor β is not altered between TGwt and
TGmut mice. As the transgene is cardiac specific, we
compared the myocardial FDG data with skeletal
muscle uptake at baseline and following insulin. As
expected, this alteration affects the heart only, with
skeletal muscle SUV values increased similarly 31% to
38% following insulin in both genotypes. This increase
correlates with previously published data in control
mice with insulin pretreatment [22].
The lack of responsiveness to cardiac insulin stimula-
tion in the PRKAG2 mutant mice, where AMPK activity
is dysfunctional, is intriguing where a link between insu-
lin stimulation and AMPK is currently under investiga-
tion with regards to type 2 diabetes [3]. The limiting
factor in our model may be the excess glycogen levels.
In a normal myocardium, insulin promotes glucose
uptake and glycogen synthesis [23]. Previous groups
have shown that when saturated with glucose, skeletal
muscles will display insulin resistance matched with a
reduction in AMPK activity [24,25]. In the current study,
an approximate fourfold increase in cardiac glycogen
stores was observed in TGmut mice. Folmes et al. [21]
reported that in adult TGmut mice, a downregulation of
Akt phosphorylation and decreased AS160 phosphoryl-
ation/expression, both of which would lead to reduced
glucose uptake. From this data, we would hypothesize,
that the increased glycogen stores are causing a negative
feedback reducing AMPK activity, and potentially alter-
ing downstream proteins in the insulin stimulated
Figure 5 Proposed interaction of AMPK on insulin signaling and GLUT4 translocation. Potential targets of AMPK to alter insulin signaling of
GLUT4 translocation through a direct inhibition of AS160 or via the mTOR pathway to inhibit Akt. The role that excessive glycogen levels play in
the PRKAG2 mutation may also contribute to myocardial insulin resistance. PI3K, phosphatidylinositol 3-kinase; PIP3, phosphatidylinositol (3,4,5)-
triphosphate; GLUT4, glucose transporter 4; PDK-1, phosphoinositide-dependent kinase-1; IRS, insulin receptor subunit.
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uptake. The lack of insulin stimulation appears to agree
with the theory that inhibition of AMPK activity amelio-
rates insulin stimulation even in the presence of glucose
deprivation.
Limitations
In this study, we used FDG as a measurement of glucose
uptake. Glucose uptake can be affected by multiple fac-
tors including but not limited to GLUT and SGL trans-
porter translocations to the cell membrane, hexokinase
activity, and glucose-6-phosphate levels. We did not
measure directly the sarcolemmal protein expression,
mRNA or whole cell activity of these factors in this
study. We recognize that free fatty acid levels affect
insulin resistance and contributes to functional changes
in the LV. However, in this study, plasma and tissue free
fatty acid levels were not evaluated. Changes in plasma
insulin levels were not measured following an acute
insulin treatment, as an increase in plasma insulin values
were expected.
Conclusions
The current findings indicate that the PRKAG2 mouse
model has reduced cardiac glucose uptake at 5 to 8
months of age, correlating with previous work [13] fromour group with reduced uptake in affected PRKAG2
patients. This reduction in cardiac uptake occurs with
reduced cardiac function, increased glycogen stores and
reduced AMPK activity. Furthermore, the PRKAG2
mouse model exhibits myocardial insulin resistance. The
findings of this study not only provide insight of the
PRKAG2 cardiac syndrome but also emphasize the
potential role of AMPK in insulin resistance observed
in other pathological cardiac states. Conversely, with
similarities to pathologic cardiac states such as type 2
diabetes, these findings provide further information on
the role that metabolic therapeutic targets may have in
the affected PRKAG2 patients.
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